Authors:
Block SL, Nolan T, Sattler C, Protocol 016 Study Group et al
Authors notes:
Pediatrics. 2006; 118:2135-45
Keywords:
immunogenicity, reactogenicity, prophylactic quadrivalent human papilloma Virus (types 6, 11, 16, and 18) L1 virus-like particle vaccine, male, female adolescents, young adult women
Abstract:
Prophylactic vaccination of 16- to 23-year-old females with a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine has been shown to prevent type-specific human papillomavirus infection and associated clinical disease. We conducted a noninferiority immunogenicity study to bridge the efficacy findings in young women to preadolescent and adolescent girls and boys, who represent a primary target for human papillomavirus vaccination.